27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
Swiss pharma giant Roche has confirmed positive data from the Phase II/III 2066 study of Ronapreve (casirivimab and imdevimab) in patients hospitalized with COVID-19. 1 October 2021
The recent ruling in favor of upholding Amgen’s patents for its phosphodiesterase inhibitor Otezla (apremilast) until its patent expiry in 2028 is an important safeguard for US biotech giant Amgen. 1 October 2021
Autogene cevumeran, an innovative cancer vaccine which could pave the way for a new class of oncology treatment, has entered into Phase II testing. 1 October 2021
Following French pharma major Sanofi’s decision this week to drop out of the race to develop coronavirus vaccines because it admits to being a late comer, the charity Médecins Sans Frontières (MSF) is urging the company to transfer the technology and know-how for the vaccine to the World Health Organization (WHO)-led COVID-19 mRNA vaccine technology transfer hub in South Africa. 1 October 2021
The Russian government, together with the Federal Antimonopoly Service (FAS), have agreed to raise prices for more than 30 drugs from the list of vital and essential since January of the current year, reports The Pharma Letter’s local correspondent. 1 October 2021
In the UK, a positive reimbursement decision has paved the way for certain people with advanced thyroid cancer to receive treatment with Eli Lilly’s Retsevmo (selpercatinib). 1 October 2021
Rumors that US pharma giant Merck & Co was interested in acquiring Acceleron Pharma proved to be well-founded after an $11.5 billion deal was confirmed today. 30 September 2021
German life sciences company Merck KGaA today announced a mutual decision with UK pharma major GlaxoSmithKline to terminate their agreement on bintrafusp alfa, effective September 30, 2021. 30 September 2021
Danish dermatology specialist LEO Pharma today announced results showing that after two years of continuous treatment with Adtralza (tralokinumab), adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference. 30 September 2021
Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry (ABPI), has written to the UK’s Chancellor of the Exchequer, Rishi Sunak, outlining the case for investing in pharma. 30 September 2021
Positive results from a Phase IIa study evaluating the safety and efficacy of amlitelimab (formerly KY1005), a human monoclonal antibody targeting key immune system regulator OX40-Ligand, were presented as a late-breaker today at the European Academy of Dermatology and Venerology (EADV) 2021 Virtual Congress. 30 September 2021
US biotech Amicus Therapeutics is to create a new genetic medicine company called Caritas Therapeutics as part of a deal that will see its gene therapy business acquired by ARYA Sciences Acquisition Corp IV (Nasdaq: ARYD), a special purpose acquisition company (SPAC). 30 September 2021
As September, Duchenne Action Month, comes to a close, we take a look at advances in pharmacological treatments for this rare condition. 30 September 2021
A global licensing agreement between Sunovion Pharmaceuticals and Japan’s Otsuka Pharmaceutical (TYO: 4578) will see the firms jointly develop and sell four compounds in neuropsychiatry. 30 September 2021
Indian drugmaker Glenmark Pharmaceuticals today announced it has received marketing approval for its fixed-dose combination nasal spray Ryaltris (olopatadine Hcl and mometasone furoate), in 13 countries across the European Union and the UK. 30 September 2021
Mirum Pharmaceuticals, a leader in rare liver disease, says that the US Food and Drug Administration has approved Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. 30 September 2021
On Wednesday, the US Food and Drug Administration issued the draft guidance for industry, “Benefit-Risk Assessment for New Drug and Biological Products.” 30 September 2021
Cuba is keen to forge joint ventures (JVs) with Indian companies for manufacturing biotech drugs and vaccines. A new joint venture established in Cuba is offering opportunities to Indian pharma and biotech companies for investments and partnerships. 29 September 2021
Chicago-based drugmaker AbbVie has had another calcitonin gene-related peptide (CGRP) receptor antagonist approved in the migraine space by the US Food and Drug Administration (FDA). 29 September 2021
Spanish plasma-derived medicines company Grifols has announced that Tavlesse (fostamatinib), used to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments, is now available in France, Italy and Spain and reimbursable from their respective health systems. 29 September 2021